# A Phase I Study of TRN501 in Healthy Volunteers

> **NCT06453551** · PHASE1 · COMPLETED · sponsor: **SNLD, Ltd.** · enrollment: 72 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** TRN501 - Dose 1
- **DRUG:** TRN501 - Dose 2
- **DRUG:** TRN501 - Dose 3
- **DRUG:** TRN501 - Dose 4
- **DRUG:** TRN501 - Dose 5
- **DRUG:** TRN501 - Dose 6
- **DRUG:** TRN501 - Dose 7
- **DRUG:** TRN501 - Dose 8

## Key facts

- **NCT ID:** NCT06453551
- **Lead sponsor:** SNLD, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-05-10
- **Primary completion:** 2024-09-20
- **Final completion:** 2024-09-20
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2025-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06453551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06453551, "A Phase I Study of TRN501 in Healthy Volunteers". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06453551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*